Research
Hormonal
Incretin hormone agonists offer substantial weight reduction and cardiometabolic benefits.
Practitioners can consider incretin hormone agonists as effective options for obesity management.
StrongSupportsmedium confidence
Incretin hormone agonists represent a significant advancement in the pharmacotherapy of obesity, offering substantial weight reduction and cardiometabolic benefits.
Why this rating
Supported by key clinical trials mentioned in the abstract.
Source
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Ibrahim S. Alhomoud et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2024
DOI 10.1002/phar.4607
reviewCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →